Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections

Clinical Infectious Diseases

Volumn 38, Issue 6, 2004, Pages 864-870

  Pankey, G A ^a   Sabath, L D ^b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BACTERICIDE; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; LINCOSAMIDE; LINEZOLID; MACROLIDE; METICILLIN; NAFCILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; TETRACYCLINE; VANCOMYCIN;

BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CLINICAL PRACTICE; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; ENDOCARDITIS; GRAM NEGATIVE INFECTION; HUMAN; IN VITRO STUDY; MENINGITIS; NEUTROPENIA; NONHUMAN; OSTEOMYELITIS; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; BACTERIAL INFECTION; DRUG EFFECT; GRAM POSITIVE BACTERIUM;

ANTI-BACTERIAL AGENTS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; TREATMENT OUTCOME;

EID: 1642311135     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/381972     Document Type: Review

References (103)

1. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001; 7:178-82.
2. Fridkin SK, Gaynes RP. Antibacterial resistance in intensive care units. Clin Chest Med 1999; 20:303-16.
3. Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med 1998; 104(Suppl 5A):7S-10S.
4. Murray BE. The life and times of the enterococcus. Clin Microbiol Rev 1990; 3:46-65.
5. Oliveira DC, Tomasz A, de Lencastre H. Secrets of success of a human pathogen: molecular evolution of pandemic clones of methicillin-resistant Staphylococcus aureus. Lancet Infect Dis 2002; 2:180-9.
6. Ploy MC, Grélaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital [letter]. Lancet 1998; 351:1212.
7. Tomasz A. New faces of an old pathogen: emergence and spread of multidrug-resistant Streptococcus pneumoniae. Am J Med 1999; 107(Suppl 1A):55S-62S.
8. Peterson LR, Shanholtzer CJ. Tests for bactericidal effects of antibacterial agents: technical performance and clinical relevance. Clin Microbiol Rev 1992; 5:420-32.
9. Vosti K. Serum bactericidal test: past, present, and future use in the management of patients with infections. In: Remington JS, Swartz MN, eds. Current clinical topics in infectious diseases, vol. 10. Oxford: Blackwell Scientific Publications, 1989:44-55.
10. Washington JA. Clinical microbiology. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious diseases. Philadelphia: WB Saunders, 1992:107-26.
11. Mulligan MJ, Cobbs CG. Bacteriostatic versus bactericidal activity. Infect Dis Clin North Am 1989; 3:389-98.
12. NCCLS. Methods for determining bactericidal activity of antibacterial agents; approved guideline. NCCLS document M26-A. Villanova, PA: NCCLS, 1999.
13. Estes L. Review of pharmacokinetics and pharmacodynamics of antibacterial agents. Mayo Clin Proc 1998; 73:1114-22.
14. Vogelman B, Craig WA. Kinetics of antibacterial activity. J Pediatr 1986; 108:835-40.
15. Handwerger S, Tomasz A. Antibiotic tolerance among clinical isolates of bacteria. Rev Infect Dis 1985; 7:368-86.
16. Peterson LR, Gerding DN, Hall WH, Schierl EA. Medium-dependent variation in bactericidal activity of antibiotics against susceptible Staphylococcus aureus. Antimicrob Agents Chemother 1978; 13:665-8.
17. Sherris JC. Problems in in vitro determination of antibiotic tolerance in clinical isolates. Antimicrob Agents Chemother 1986; 30:633-7.
18. Taylor PC, Schoenknecht FD, Sherris JC, Linner EC. Determination of minimum bactericidal concentrations of oxacillin for Staphylococcus aureus: influence and significance of technical factors. Antimicrob Agents Chemother 1983; 23:142-50.
19. Kim KS, Anthony BF. Importance of bacterial growth phase in determining minimal bactericidal concentrations of penicillin and methicillin. Antimicrob Agents Chemother 1981; 19:1075-7.
20. Eng RH, Padberg FT, Smith SM, Tan EN, Cherubin CE. Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria. Antimicrob Agents Chemother 1991; 35:1824-8.
21. Mayhall CG, Medoff G, Marr JJ. Variation in the susceptibility of strains of Staphylococcus aureus to oxacillin, cephalothin, and gentamicin. Antimicrob Agents Chemother 1976; 10:707-12.
22. Barry AL, Lasner RA. In-vitro methods for determining minimum lethal concentrations of antibacterial agents. Am J Clin Pathol 1979; 71:88-92.
23. Dankert J, Holloway Y, Joldersma W, Hess J. Importance of minimizing carry-over effect at subculture in the detection of penicillin-tolerant viridans group streptococci. Antimicrob Agents Chemother 1983; 23:614-6.
24. Garrod LP. The action of penicillin on bacteria. Br Med J 1945; 1:107-10.
25. Lamp KC, Rybak MJ. Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calcium. Antimicrob Agents Chemother 1993; 37:605-9.
26. Venglarcik JS III, Blair LL, Dunkle LM. pH-dependent oxacillin tolerance of Staphylococcus aureus. Antimicrob Agents Chemother 1983; 23:232-5.
27. Woolfrey BF, Gresser-Burns ME, Lally RT. Effect of temperature on inoculum as a potential source of error in agar dilution plate count bactericidal measurements. Antimicrob Agents Chemother 1988; 32:513-7.
28. Eagle H, Mussleman AD. Slow recovery of bacteria from toxic effects of penicillin. J Bacteriol 1949; 58:475-90.
29. Anhalt, JP, Sabath LK, Barry AL. Special tests: bactericidal activity, activity of antimicrobics in combination, and detection of β-lactamase production. In: Lennette EH, Balows A, Hausler WJ Jr, Truant JP, eds. Manual of clinical microbiology. 3rd ed. Washington, DC: American Society for Microbiology Press, 1980:478-84.
30. Greenwood D. Phenotypic resistance to antibacterial agents. J Antimicrob Chemother 1985; 15:653-5.
31. Jones EM, MacGowan AP. The antibacterial chemotherapy of human infection due to Listeria monocytogenes. Eur J Clin Microbiol Infect Dis 1995; 14:165-75.
32. MacGowan AP, Bowker KE. Pharmacodynamics of antibacterial agents and rationale for their dosing. J Chemother 1997; 9(Suppl 1):64-73.
33. Reese RE, Betts RF. Antibiotic use. In: Reese RE, Betts RF, eds. A practical approach to infectious diseases. 3rd ed. Boston: Little, Brown, and Company, 1991:821-1007.
34. Tuomanen E. Phenotypic tolerance: the search for beta-lactam antibiotics that kill nongrowing bacteria. Rev Infect Dis 1986; 8(Suppl 3):S279-91.
35. Tuomanen E, Durack DT, Tomasz A. Antibiotic tolerance among clinical isolates of bacteria. Antimicrob Agents Chemother 1986; 30:521-7.
36. van Asselt GJ, Mouton RP, van Boven CPA. Penicillin tolerance and treatment failure in Group A streptococcal pharyngotonsillitis. Eur J Clin Microbiol Infect Dis 1996; 15:107-15.
37. James PA. Comparison of four methods for determination of MIC and MBC of penicillin for viridans streptococci and implications for penicillin tolerance. J Antimicrob Chemother 1990; 25:209-16.
38. Svenungsson B, Kalin M, Lindgren LG. Therapeutic failure in pneumonia caused by a tolerant strain of Staphylococcus aureus. Scand J Infect Dis 1982; 14:309-11.
39. Denny AE, Peterson LR, Gerding DN, Hall WH. Serious staphylococcal infections with strains tolerant to bactericidal antibiotics. Arch Intern Med 1979; 139:1026-31.
40. Griffiths LR, Green HT. Paradoxical effect of penicillin in-vivo [letter]. J Antimicrob Chemother 1985; 15:507-8.
41. Sabath LD, Wheeler N, Lavadiere M, Blazevic D, Wilkinson BJ. A new type of penicillin resistance in Staphylococcus aureus. Lancet 1977; 1:443-7.
42. Fernandes PB, Bailer R, Swanson R, et al. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother 1986; 30:865-73.
43. Haight TH, Finland M. Observations on mode of action of erythromycin. Proc Soc Exper Biol Med 1952; 81:188-93.
44. Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992; 11:137-52.
45. Retsema J, Girard A, Schelkly W, et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother 1987; 31:1939-47.
46. Feder HM Jr, Osier C, Maderazo EG. Chloramphenicol: a review of its use in clinical practice. Rev Infect Dis 1981; 3:479-91.
47. Rahal JJ Jr, Simberkoff MS. Bactericidal and bacteriostatic action of chloramphenicol against meningeal pathogens. Antimicrob Agents Chemother 1979; 16:13-8.
48. Turk DC. A comparison of chloramphenicol and ampicillin as bactericidal agents for Haemophilus influenzae type B. J Med Microbiol 1977; 10:127-31.
49. Weeks JL, Mason EO Jr, Baker CJ. Antagonism of ampicillin and chloramphenicol against meningeal isolates of group B streptococci. Antimicrob Agents Chemother 1981; 20:281-5.
50. Nastro LJ, Finegold SM. Bactericidal activity of five antibacterial agents against Bacteroides fragilis. J Infect Dis 1972; 126:104-7.
51. Sande MA, Johnson ML. Antibacterial therapy of experimental endocarditis caused by Staphylococcus aureus. J Infect Dis 1975; 131:367-75.
52. Bostic GD, Perri MB, Thal LA, Zervos MJ. Comparative in vitro bactericidal activity of oxazolidone antibiotics against multidrug-resistant enterococci. Diagn Microbiol Infect Dis 1998; 30:109-12.
53. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40:839-45.
54. Delgado G Jr, Neuhauser MM, Bearden DT, Danziger LH. Quinupristin- dalfopristin: an overview. Pharmacotherapy 2000; 20:1469-85.
55. Lamb HM, Figgitt DP, Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs 1999; 58:1061-97.
56. Crumplin GC, Smith JT. Nalidixic acid: an antibacterial paradox. Antimicrob Agents Chemother 1975; 8:251-61.
57. Smith JT, Lewin CS. Chemistry and mechanisms of action of the quinolone antibacterials. In: Andriole VT, ed. The quinolones. London: Academic Press, 1988:23-81.
58. Levison ME, Bush LM. Pharmacodynamics of antibacterial agents: bactericidal and postantibiotic effects. Infect Dis Clin North Am 1989; 3:415-21.
59. Cantoni L, Glauser MP, Bille J. Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob Agents Chemother 1990; 34:2348-53.
60. Sullam PM, Drake TA, Täuber MG, Hackbarth CJ, Sande MA. Influence of the developmental state of valvular lesions on the antibacterial activity of cefotaxime in experimental enterococcal infections. Antimicrob Agents Chemother 1985; 27:320-3.
61. Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988; 158:23-8.
62. Stevens DL, Maier KA, Laine BM, Mitten JE. Comparison of clindamycin, rifampin, tetracycline, metronidazole and penicillin for efficacy in prevention of experimental gas gangrene due to Clostridium perfringens. J Infect Dis 1987; 155:220-8.
63. Craig W. Pharmacodynamics of antibacterial agents as a basis for determining dosage regimens. Eur J Clin Microbiol Infect Dis 1993; 12(Suppl 1):S6-8.
64. Odio W, Van Laer E, Klastersky J. Concentrations of gentamicin in bronchial secretions after intramuscular and endotracheal administration. J Clin Pharmacol 1975; 15:518-24.
65. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984; 77:657-62.
66. Gristina AG, Costerton JW. Bacterial adherence and the glycocalyx and their role in musculoskeletal infection. Orthop Clin North Am 1984; 15:517-35.
67. Lambe DW Jr, Mayberry-Carson KJ, Ferguson KP. Morphological stabilization of the glycocalyces of 23 strains of five Bacteroides species using specific antisera. Can J Microbiol 1984; 30:809-19.
68. Mayberry-Carson KJ, Tober-Meyer B, Smith JK, Lambe DW Jr, Costerton JW. Bacterial adherence and glycocalyx formation in osteomyelitis experimentally induced with Staphylococcus aureus. Infect Immun 1984; 43:825-33.
69. Speers DJ, Nade SM. Ultrastructural studies of adherence of Staphylococcus aureus in experimental acute hematogenous osteomyelitis. Infect Immun 1985; 49:443-6.
70. Mayberry-Carson KJ, Mayberry WR, Tober-Meyer BK, Costerton JW, Lambe DW Jr. An electron microscopic study of the effect of clindamycin on adherence of Staphylococcus aureus to bone surfaces. Microbios 1986; 45:21-32.
71. Mayberry-Carson KJ, Tober-Meyer B, Lambe DW Jr, Costerton JW. An electron microscopic study of the effect of clindamycin therapy on bacterial adherence and glycocalyx formation in experimental Staphylococcus aureus osteomyelitis. Microbios 1986; 48:189-206.
72. Proctor RA, Olbrantz PJ, Mosher DF. Subinhibitory concentrations of antibiotics alter fibronectin binding to Staphylococcus aureus. Antimicrob Agents Chemother 1983; 24:823-6.
73. Durack DT, Beeson PB. Experimental bacterial endocarditis. I. Colonization of a sterile vegetation. Br J Exp Pathol 1972; 53:44-9.
74. Neu HC. General therapeutic principles. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious diseases. Philadelphia: WB Saunders, 1992:153-60.
75. Brandriss MW, Lambert JS. Cardiac infections. In: Reese RE, Betts RF, eds. A practical approach to infectious diseases. 3rd ed. Boston: Little, Brown, and Company, 1991:278-304.
76. Hunter TH. Speculations on mechanism of cure of bacterial endocarditis. JAMA 1950; 144:524-7.
77. Watanakunakorn C. Clindamycin therapy of Staphylococcus aureus endocarditis: clinical relapse and development of resistance to clindamycin, lincomycin and erythromycin. Am J Med 1976; 60:419-25.
78. Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med 1982; 97:496-503.
79. Musher DM, McKenzie SO. Infections due to Staphylococcus aureus. Medicine (Baltimore) 1977; 56:383-409.
80. Scheld WM, Sande MA. Cardiovascular infections. In: Mandell GL, Douglas RG, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:740-83.
81. Babcock HM, Ritchie DJ, Christiansen E, Starlin R, Little R, Stanley S. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 2001; 32:1373-5.
82. Moise PA, Forrest A, Birmingham MC, Schentag JJ. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 2002; 50:1017-26.
83. Hoyne AL, Simon DL. Intramuscular terramycin in treatment of meningitis; report of 21 recoveries. Arch Pediatr 1953:70:319-25.
84. Paredes A, Taber LH, Yow MD, Clark D, Nathan W. Prolonged pneumonococcal meningitis due to an organism with increased resistance to penicillin. Pediatrics 1976; 58:378-81.
85. Shaikh ZH, Peloquin CA, Ericsson CD. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infect Dis 2001; 33:375-9.
86. Zeana C, Kubin CJ, Della-Latta P, Hammer SM. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin Infect Dis 2001; 33:477-82.
87. Levitz RE, Quintiliani R. Trimethoprim/sulfamethoxazole for bacterial meningitis. Ann Intern Med 1984; 100:881-90.
88. Quintiliani R, Levitz RE, Nightingale CH. Potential role of trimethoprim-sulfamethoxazole in the treatment of serious hospital-acquired bacterial infections. Rev Infect Dis 1987; 9(Suppl 2):160-7.
89. Scheld WM, Sande MA. Bactericidal versus bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits. J Clin Invest 1983; 71:411-9.
90. Friedland IR, Klugman KP. Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis. Lancet 1992; 339:405-8.
91. Chapman SW, Lin AC. Osteomyelitis and diabetic foot infections. In: Reese RE, Betts RF, eds. A practical approach to infectious diseases. 3rd ed. Boston: Little, Brown, and Company, 1991:464-98.
92. Mader JT, Landon GC, Calhoun J. Antimicrobial treatment of osteomyelitis. Clin Orthop 1993; 295:87-95.
93. Klastersky J. Concept of empiric therapy with antibiotic combinations: indications and limits. Am J Med 1986; 80(Suppl 5C):2-12.
94. Young LS. Empirical antimicrobial therapy in the neutropenic host [editorial]. N Engl J Med 1986; 315:580-1.
95. Brown AE. Neutropenia, fever, and infection. Am J Med 1984; 76:421-8.
96. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315:552-8.
97. Jackson JJ, Kropp H. β-Lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime. J Infect Dis 1992; 165:1033-41.
98. Quagliarello V, Scheld WM. Bacterial meningitis: pathogenesis, pathophysiology, and progress. N Engl J Med 1992; 327:864-72.
99. Arditi M, Manogue KR, Caplan M, Yogev R. Cerebrospinal fluid cachectin/tumor necrosis factor-α and platelet-activating factor concentrations and severity of bacterial meningitis in children. J Infect Dis 1990; 162:139-47.
100. Mustafa MM, Mertsola J, Ramilo O, Saez-Llorens X, Risser RC, McCracken GH Jr. Increased endotoxin and interleukin-1β concentrations in cerebrospinal fluid of infants with coliform meningitis and ventriculitis associated with intraventricular gentamicin therapy. J Infect Dis 1989; 160:891-5.
101. Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 2002; 15:95-110.
102. van Langevelde P, van Dissel JT, Meurs CJC, Renz J, Groeneveld PHP. Combination of flucloxacillin and gentamicin inhibits toxic shock syndrome toxin 1 production by Staphylococcus aureus in both logarithmic and stationary phases of growth. Antimicrob Agents Chemother 1997; 41:1682-5.
103. Russell NE, Pachorek RE. Clindamycin in the treatment of streptococcal and staphylococcal toxic shock syndromes. Ann Pharmacother 2000; 34:936-9.